证券代码：605199 证券简称：葫芦娃 公告编号：2024-029 海南葫芦娃药业集团股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日分别收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的盐酸溴己新注射液、地氯雷他定片的《药 品注册证书》。现将有关情况公告如下： 一、盐酸溴己新注射液 （一）药品基本情况 药物名称：盐酸溴己新注射液 剂型：注射剂 注册分类：化学药品 3 类 规格：2ml:4mg 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2201492 药品批准文号：国药准字 H20243551 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工 艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 （二）药品研发及相关 盐酸溴己新有较强的溶解黏痰作用，可使痰中的多糖纤维素裂解，稀化 ...

环境、社会与公司治理 (ESG) 报告 2023 海南葫芦娃药业集团股份有限公司 | 目录 | 报告编制说明 | 4 | | --- | --- | --- | | | 公司介绍 | 6 | | | 公司概况 | 6 | | S | 2023 年度关键量化绩效 ESG 管理 | 8 9 | | T | ESG 管理体系 | 9 | | | 利益相关方沟通 | 10 | | N | 实质性议题分析 | 11 | | E | 党建引领，优化企业治理 | 12 | | | 党建引领 | 12 | | T | 公司治理 风险管理与内部控制 | 13 15 | | N | 反腐败与商业道德 关爱环境，推动绿色发展 | 15 16 | | O | 环境管理体系 资源管理 | 16 19 | | C | 排放物与废弃物 | 21 | | | 应对气候变化 | 26 | | | 创新驱动，提升产品服务 | 29 | | | 研发与创新 | 29 | | | 产品质量与安全 | 33 | | | 客户服务 | 39 | | | 供应商管理 | 42 | | | 以人为本，打造和谐职场 | 44 | | | 员工雇佣及福利 | ...

海南葫芦娃药业集团股份有限公司董事会审计委员会 对会计师事务所 2023 年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》和《海南葫芦娃药业集团 股份有限公司章程》《海南葫芦娃药业集团股份有限公司审计委员会工作细则》等 规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。2023 年，公司聘请的财务审计机构和内部控制审计机构为安永华明会计师事务所（特殊 普通合伙）（以下简称"安永华明"）。现将董事会审计委员会对会计师事务所 2 023 年度履行监督职责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 安永华明于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合作 的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京，注册 地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。截至 2023 年 末拥有合伙人 245 人，首席合伙人为毛鞍宁先生。安永华明一直以来注重人才培 养，截至 2023 年末 ...

海南葫芦娃药业集团股份有限公司 2023 年度独立董事述职报告 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《上海证券交 易所股票上市规则》、《上市公司自律监管指引第1号——规范运作》等法律法规以及 《海南葫芦娃药业集团股份有限公司章程》(以下简称"《公司章程》")、和《海南 葫芦娃药业集团股份有限公司独立董事工作制度》等相关规定和要求，作为海南葫芦 娃药业集团股份有限公司（以下简称"公司"）独立董事，现就 2023年度履职情况述 职如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 刘秋云，女，1979年出生，中国国籍，无境外永久居留权，本科学历，2016年8月至 2020年3月担任海南蛛王生物科技有限公司财务经理；2020年4月至2022年8月担任海南 自贸区珈宝置业集团有限公司财务总监；2022年9月至今担任海南迈迪能源科技有限公 司财务总监，2022年11月至今担任本公司独立董事。 （二）独立性情况说明 作为公司独立董事，本人及直系亲属、主要社会关系均不在公司或其附属企业任职， 未直接或间接持有公司股份，不在直接或间接持有公司已发行股份5%或5%以上的股东单 位任职 ...

海南葫芦娃药业集团股份有限公司 2023 年度董事会审计委员会履职情况报告 根据中国证监会《上市公司治理准则》、上海证券交易所《股票上市规则》、 《上市公司自律监管指引第 1 号——规范运作》及公司《董事会审计委员会工作细 则》等有关规定和《公司章程》等相关文件要求，本着勤勉尽责的原则、积极开展 工作，认真履行职责。现将审计委员会 2023 年度履职情况向董事会报告如下： 一、董事会审计委员会基本情况 本公司董事会审计委员会由 3 名董事组成。报告期内，第三届董事会审计委员 会成员为独立董事刘秋云、王世贤和非独立董事李君玲 3 名成员组成，由会计专业 人士的独立董事刘秋云担任召集人。公司已于 2023 年 8 月 28 日召开第三届董事会 第二次会议审议通过了《关于调整董事会专门委员会成员的议案》，公司董事会审 计委员会成员由刘秋云、王世贤、李君玲调整成刘秋云、王世贤、汤琪波。 1、监督及评估公司年度报告的审计工作情况 刘秋云，女，1979 年出生，中国国籍，无境外永久居留权，本科学历，2016 年 8 月至 2020 年 3 月担任海南蛛王生物科技有限公司财务经理；2020 年 4 月至 20 22 年 8 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-028 海南葫芦娃药业集团股份有限公司 关于办公地址及投资者联系方式变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 办公地址：海南省海口市秀英区安读一路30号 投资者联系电话：0898- 68634767 投资者传真号码：0898- 68631245 投资者邮箱：huluwa@huluwayaoye.com 特此公告。 海南葫芦娃药业集团股份有限公司董事会 2024 年 4 月 26 日 1 海南葫芦娃药业集团股份有限公司（以下简称"公司"）将于2024年5 月9日起搬迁到新址办公，现将公司新的办公地址及投资者联系方式变更情 况公告如下： ...

Financial Performance - The company's operating revenue for 2023 reached ¥1,905,182,163.02, representing a 25.75% increase compared to ¥1,515,046,453.62 in 2022[24] - Net profit attributable to shareholders of the listed company was ¥106,497,782.30, up 24.29% from ¥85,681,971.00 in the previous year[24] - The net profit after deducting non-recurring gains and losses was ¥81,806,805.66, reflecting a 20.21% increase from ¥68,053,308.12 in 2022[24] - The company's cash flow from operating activities was ¥28,252,316.37, a significant decrease of 88.16% compared to ¥238,711,442.29 in 2022[24] - The net assets attributable to shareholders of the listed company increased by 10.50% to ¥1,120,385,678.79 from ¥1,013,887,896.49 at the end of 2022[24] - The basic earnings per share increased to 0.27 yuan, reflecting a growth of 28.57% year-on-year[26] - The weighted average return on equity rose to 9.98%, an increase of 1.16 percentage points from the previous year[26] - The gross profit margin decreased by 5.08 percentage points to 52.77% due to a 40.91% increase in operating costs[86] Dividend and Shareholder Returns - The proposed cash dividend for 2023 is ¥1.25 per 10 shares, totaling ¥50,013,594 (including tax), which accounts for 46.96% of the net profit attributable to shareholders[6] - The company does not plan to issue new shares or increase capital reserves this year[6] - The profit distribution plan is subject to approval at the company's 2023 annual general meeting[200] Research and Development - The company has 128 products under research, with approximately 50% focused on pediatric applications, particularly in respiratory and digestive systems[36] - The company actively invests in R&D, with established research centers and collaborations to enhance innovation capabilities[53] - The company is committed to enhancing its R&D capabilities in pediatric and traditional Chinese medicine through various collaboration and innovation strategies[57] - Total R&D investment reached 147.77 million RMB, accounting for 7.76% of operating revenue[100] - The company is increasing its R&D investments, focusing on multiple formulation developments and consistency evaluation projects, which may impact its financial performance[163] Product Development and Market Strategy - The company launched three new products during the reporting period, enhancing its product portfolio and supporting sustainable development[72] - The company is focusing on expanding its marketing network to include new retail channels, adapting to national healthcare policies[80] - The company has established a marketing strategy focused on "market-oriented and consumer-centered" approaches, targeting medical institutions and retail pharmacies while expanding e-commerce channels[69] - The company is positioned to deepen its involvement in the pediatric medicine market, particularly in R&D, to better serve children's health needs[56] Quality Control and Compliance - The company achieved a 100% product pass rate, ensuring strict quality control and adherence to production standards[38] - The company has established a robust quality management system, including ICH Q10 and ISO9001 certifications, ensuring high standards in drug production and quality control[75] - The company has strengthened its governance and risk management systems, ensuring compliance and enhancing organizational effectiveness[40] Market Trends and Industry Insights - In 2023, the pharmaceutical manufacturing industry in China generated revenue of CNY 25,205.7 billion, with stable market demand and sales growth outpacing overall levels[47] - The government has introduced policies to support pediatric drug development, creating a favorable environment for growth in the pediatric drug market[51] - The company acknowledges the risk of intensified market competition in the pediatric medication sector and other therapeutic areas due to increasing market demand and new entrants[164] Corporate Governance and Management - The company has established a dedicated board secretary to manage investor relations and ensure compliance with information disclosure regulations[170] - The board of directors and supervisory board strictly adhere to their responsibilities and obligations as outlined in the company's articles of association[170] - The company has implemented measures to prevent information leakage and ensure fairness in information disclosure[170] Sustainability and Social Responsibility - The company is committed to creating a national-level green factory, focusing on energy conservation and environmental protection, with ongoing investments in sustainable development[43] - The company has been recognized as a "No Waste Pharmaceutical Enterprise" by local authorities, reflecting its commitment to sustainable practices[43] - The management team emphasizes a commitment to sustainability and corporate social responsibility in future business strategies[176] Employee and Talent Management - The company emphasizes talent development through a comprehensive training system, including new employee orientation and specialized skills training for various roles[198] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 6.9185 million RMB[183] - The company has established a performance assessment system to create a competitive salary structure, linking employee compensation closely with job responsibilities and performance[197] Future Outlook and Strategic Initiatives - The company plans to expand its market presence and is exploring potential mergers and acquisitions to enhance its competitive edge[176] - The company aims to improve patient outcomes through innovative therapies and expanded access to medications[127] - The company anticipates continued growth in the pharmaceutical sector, supported by ongoing research and development initiatives[110]

证券代码：605199 证券简称：葫芦娃 公告编号：2024-022 海南葫芦娃药业集团股份有限公司 关于续聘 2024 年度财务审计机构和 内部控制审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 安永华明及从业人员近三年没有因执业行为受到任何刑事处罚、行政处罚，以及行 业协会等自律组织的自律监管措施和纪律处分。曾收到证券监督管理机构出具警示函一 次，涉及两名从业人员。前述出具警示函的决定属监督管理措施，并非行政处罚。曾收 到深圳证券交易所对本所的两名从业人员出具书面警示的自律监管措施一次，亦不涉及 处罚。根据相关法律法规的规定，前述监管措施不影响安永华明继续承接或执行证券服 务业务和其他业务。 拟聘任的会计师事务所名称：安永华明会计师事务所(特殊普通合伙) 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 安永华明会计师事务所（特殊普通合伙）以下简称"安永华明"，于 1992 年 9 月成 立，2012 年 8 月完成本土化转制，从一家中外合作的有限责任制事务所转制为特殊普通 合 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-027 海南葫芦娃药业集团股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 股东大会召开日期：2024年5月22日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 22 日 至 2024 年 5 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 430,405,183.89, representing a decrease of 18.37% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2024 was CNY 29,032,483.80, down 28.42% year-on-year[5]. - The basic earnings per share for Q1 2024 was CNY 0.07, reflecting a decline of 30.00% compared to the previous year[5]. - Total operating revenue for Q1 2024 was CNY 430.41 million, a decrease of 18.4% compared to CNY 527.26 million in Q1 2023[17]. - Net profit for Q1 2024 was CNY 30.16 million, a decline of 25.4% from CNY 40.42 million in Q1 2023[19]. - Earnings per share for Q1 2024 were CNY 0.07, compared to CNY 0.10 in Q1 2023[20]. Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY -190,443,500.39, indicating a significant cash outflow[5]. - Cash flow from operating activities in Q1 2024 was negative CNY 190.44 million, worsening from negative CNY 118.33 million in Q1 2023[24]. - Cash outflow from operating activities totaled CNY 496.73 million in Q1 2024, compared to CNY 482.50 million in Q1 2023[24]. - Investment activities generated a net cash outflow of CNY 91.93 million in Q1 2024, compared to CNY 123.10 million in Q1 2023[24]. - Cash inflow from financing activities in Q1 2024 was CNY 98.98 million, significantly lower than CNY 257.35 million in Q1 2023[24]. - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 5.88 million in Q1 2024 from CNY 3.81 million in Q1 2023[17]. - In Q1 2024, the company reported a net cash flow from financing activities of -$1,692,343.71, a significant decrease compared to $100,205,850.47 in Q1 2023[25]. - The total cash and cash equivalents at the end of Q1 2024 were $236,868,072.80, down from $322,610,823.41 in Q1 2023, reflecting a decrease of approximately 26.5%[25]. - The cash outflow from financing activities totaled $100,672,343.71 in Q1 2024, compared to $157,139,915.35 in the same period last year, indicating a reduction of about 36%[25]. - The company experienced a net decrease in cash and cash equivalents of $284,069,641.62 in Q1 2024, compared to a decrease of $141,230,543.14 in Q1 2023[25]. - The beginning cash and cash equivalents balance for Q1 2024 was $520,937,714.42, which is an increase from $463,841,366.55 in Q1 2023[25]. Assets and Liabilities - The total assets at the end of Q1 2024 were CNY 3,028,414,701.53, a decrease of 1.05% from the end of the previous year[6]. - As of March 31, 2024, the company's total assets amounted to RMB 3,028,414,701.53, a decrease from RMB 3,060,548,675.78 as of December 31, 2023, reflecting a decline of approximately 1.06%[14]. - The company's cash and cash equivalents decreased to RMB 251,166,833.49 from RMB 522,689,865.24, representing a significant decline of about 52.0%[14]. - Current liabilities totaled RMB 1,214,446,409.49, up from RMB 1,082,500,727.83, reflecting an increase of approximately 12.2%[16]. - The company's long-term borrowings decreased to RMB 543,678,654.80 from RMB 737,428,654.80, a reduction of about 26.3%[16]. - The total liabilities decreased to RMB 1,838,677,753.43 from RMB 1,901,175,403.43, indicating a decline of approximately 3.3%[16]. - The retained earnings increased to RMB 394,131,600.27 from RMB 365,099,116.47, reflecting a growth of about 7.1%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,421[11]. - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., held 41.76% of the shares, totaling 167,079,000 shares[11]. Other Financial Metrics - The weighted average return on equity for Q1 2024 was 2.56%, a decrease of 1.36 percentage points year-on-year[5]. - The company reported a government subsidy of CNY 6,328,051.96, which is included in non-operating income[7]. - Accounts receivable increased to RMB 557,741,207.29 from RMB 540,600,831.70, showing a growth of approximately 3.2%[14]. - Inventory rose to RMB 306,845,689.51 from RMB 265,561,874.47, indicating an increase of around 15.5%[15]. - The company's long-term equity investments increased to RMB 22,959,989.94 from RMB 20,444,191.34, showing a growth of about 12.3%[15]. - The company reported a significant increase in prepayments, which rose to RMB 73,931,621.66 from RMB 25,522,559.90, marking an increase of approximately 189.5%[14]. - Total operating costs for Q1 2024 were CNY 402.98 million, down 13.7% from CNY 467.07 million in Q1 2023[17].